middle.news
Vectus Appoints Dr Tara Speranza to Lead VB0004 Clinical Push
7:03pm on Thursday 7th of May, 2026 AEST
•
Healthcare
Read Story
Vectus Appoints Dr Tara Speranza to Lead VB0004 Clinical Push
7:03pm on Thursday 7th of May, 2026 AEST
Key Points
Dr Tara Speranza appointed CEO and CTO
Over 20 years in biotech research and capital markets
Focus on advancing VB0004 through clinical and partnership milestones
Performance securities represent 2% of fully diluted capital
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE